Yong Ben Biography and Net Worth

Director of Corbus Pharmaceuticals

Dr. Ben has over 25 years of medical experience in academia and pharmaceutical and biotech companies, including clinical practice, drug discovery and development in oncology and hematological malignancies. He is currently Chief Medical Officer of Bridge Bio Oncology Therapeutics. Prior to that, he was a venture partner at Eight Roads Venture (formerly known as Fidelity Ventures). Prior to Eight Roads Venture, he was Chief Medical Officer, Solid Tumors at BeiGene. Prior to BeiGene, Dr. Ben served as Chief Medical Officer at San Diego-based biotech company BioAtla. Previously, he was global clinical leader of immuno-oncology clinical development at AstraZeneca, leading the approval of durvalumab in urothelial cancer. Dr. Ben's career highlights also include his work on the approval of ixazomib in multiple myeloma at Millennium Pharmaceuticals and the approval of axitinib in renal cancer at Pfizer. He started his career as a surgical oncologist at Peking Union Medical College Hospital and completed a postdoctoral fellowship at California Pacific Medical Center. Dr. Ben received his medical degree from Norman Bethune College of Medicine and his MBA from the University of California, San Diego.

What is Yong Ben's net worth?: The estimated net worth of Yong Ben is at least $64.93 thousand as of September 14th, 2026. Dr. Ben owns 9,383 shares of Corbus Pharmaceuticals stock worth more than $64,930 as of September 16th. This net worth approximation does not reflect any other assets that Dr. Ben may own. Learn More about Yong Ben's net worth.
How do I contact Yong Ben?: The corporate mailing address for Dr. Ben and other Corbus Pharmaceuticals executives is 500 River Ridge Drive, Norwood MA, 02062. Corbus Pharmaceuticals can also be reached via phone at (617) 963-0100 and via email at [email protected]. Learn More on Yong Ben's contact information.
Has Yong Ben been buying or selling shares of Corbus Pharmaceuticals?: During the last quarter, Yong Ben has sold $15,680.00 in Corbus Pharmaceuticals stock. Most recently, Yong Ben sold 2,000 shares of the business's stock in a transaction on Monday, September 14th. The shares were sold at an average price of $7.84, for a transaction totalling $15,680.00. Following the completion of the sale, the director now directly owns 9,383 shares of the company's stock, valued at $73,562.72. Learn More on Yong Ben's trading history.
Who are Corbus Pharmaceuticals' active insiders?: Corbus Pharmaceuticals' insider roster includes Anne Altmeyer (Director), Yong Ben (Director), Yuval Cohen (CEO), Ian Hodgson (COO), John Jenkins (Director), Winston Kung (Director), Sean Moran (CFO), and Nishant Saxena (Insider). Learn More on Corbus Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Corbus Pharmaceuticals?: During the last twelve months, Corbus Pharmaceuticals insiders bought shares 3 times. They purchased a total of 16,100 shares worth more than $126,243.00. During the last twelve months, insiders at the biopharmaceutical company sold shares 13 times. They sold a total of 117,641 shares worth more than $1,485,188.36. The most recent insider tranaction occured on September, 14th when Director Yong Ben sold 2,000 shares worth more than $15,680.00. Insiders at Corbus Pharmaceuticals own 3.5% of the company. Learn More about insider trades at Corbus Pharmaceuticals.
Information on this page was last updated on 9/14/2026.

Yong Ben Insider Trading History at Corbus Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/14/2026	Sell	2,000	$7.84	$15,680.00	9,383

Yong Ben Buying and Selling Activity at Corbus Pharmaceuticals

Corbus Pharmaceuticals Company Overview

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Today's Range

Now: $7.21

$6.88

50 Day Range

MA: $9.70

$6.92

$11.48

2 Week Range

Now: $7.21

$6.32

$20.56

Volume

6,694 shs

Average Volume

438,798 shs

Market Capitalization

$134.67 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.63